CURIS INC (CRIS)
US2312693094 - Common Stock
Curis Provides Third Quarter 2024 Business Update
/PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
/PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...
Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis to Present at Upcoming Healthcare Conference in July
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Announces Additional Data from TakeAim Leukemia Study
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis to Present Updated Data from the TakeAim Leukemia Study
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
CRIS Stock Earnings: Curis Beats EPS, Misses Revenue for Q1 2024
CRIS stock results show that Curis beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Curis Provides First Quarter 2024 Business Update
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Curis to Present at Upcoming Healthcare Conferences in April
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Curis, Inc. (NASDAQ: CRIS) on behalf of the company's shareholders. The...
Curis files for $300M common stock offering (NASDAQ:CRIS)
Curis (CRIS) filed a prospectus for a mixed shelf offering to raise $25M. This is not an offer to sell the securities mentioned.
Curis Provides Fourth Quarter 2023 Business Update
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...
Curis Provides Third Quarter 2023 Business Update
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...